13F Holdings
中文EN

GERN GERON CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 886744 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY40.2%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-20.1%
ROA-8.7%
ROIC (approx.)-8.9%
Asset turnover—

Leverage & solvency

Liabilities / assets57.0%
Debt / equity0.53x
Current ratio6.31x
Interest coverage-1.11x

Cash quality & payout

Operating cash flow / net income1.89x
Accruals ratio7.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$237,000$596,000$1.39M
R&D expense$71.43M$103.74M$125.05M$95.52M$85.73M
SG&A expense$159.26M$145.73M$69.14M$43.63M$29.66M
Operating income-$68.58M-$173.73M-$193.94M-$138.55M-$114.00M
Interest expense$32.66M$18.50M$8.31M$6.88M$3.74M
Pretax income-$83.42M-$174.52M-$181.73M-$141.90M—
Income tax$75,000$449,000$22,000——
Net income-$83.50M-$174.57M-$184.13M-$141.90M-$116.11M
EBITDA-$68.11M-$173.19M-$193.50M-$138.26M-$113.78M
EPS (basic)-0.13-0.27-0.32-0.37-0.35
EPS (diluted)-0.13-0.27-0.32-0.37-0.35
Weighted avg. shares (diluted)666.66M646.03M570.65M380.78M327.63M
Balance sheet
Cash & equivalents$77.56M$79.02M$70.02M$56.84M$34.87M
Short-term investments—$327.55M$263.68M$115.90M$148.85M
Receivables$36.99M$35.95M———
Inventory$116.64M$38.71M———
Current assets$520.27M$490.99M$341.35M$180.25M$187.21M
PP&E, net$884,000$1.31M$1.18M$793,000$650,000
Total assets$570.54M$593.78M$394.08M$190.57M$226.03M
Current liabilities$111.54M$88.30M$108.07M$76.69M$45.52M
Short-term debt—$0$46.89M$20.95M—
Long-term debt$119.55M$118.48M$35.05M$30.21M$49.83M
Total debt$119.55M$118.48M$81.94M$51.16M$49.83M
Total liabilities$344.67M$313.46M$146.13M$110.58M$99.62M
Shareholders' equity$225.87M$280.32M$247.95M$80.00M$126.42M
Net debt$41.99M$39.46M$11.92M-$5.69M$14.96M
Shares outstanding639.86M606.39M544.91M390.26M323.73M
Cash flow statement
Operating cash flow-$111.04M-$218.62M-$167.74M-$127.38M-$95.56M
Capital expenditure—$680,000$830,000$431,000$207,000
Free cash flow—-$219.30M-$168.57M-$127.81M-$95.76M
Investing cash flow$107.25M-$106.00M-$180.32M$62.07M$71.95M
Financing cash flow$2.27M$334.37M$362.02M$87.26M$48.56M
Depreciation & amortization$474,000$546,000$442,000$288,000$215,000
Stock-based compensation$26.66M$31.18M$18.53M$8.00M$8.08M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.